Corbus Pharmaceuticals Analyst Ratings
Corbus Pharmaceuticals Analyst Ratings
While ratings are subjective and will change, the latest Corbus Pharmaceuticals (CRBP) rating was a reiterated with a price target of $0.00 to $22.00. The current price Corbus Pharmaceuticals (CRBP) is trading at is $6.44, which is within the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/09/2023 | 241.61% | Oppenheimer | → $22 | Reiterates | Outperform → Outperform |
| 05/10/2023 | 241.61% | Oppenheimer | → $22 | Upgrades | Perform → Outperform |
| 03/08/2023 | -53.42% | HC Wainwright & Co. | → $3 | Reiterates | → Buy |
| 02/14/2023 | -53.42% | HC Wainwright & Co. | → $3 | Reiterates | → Buy |
| 10/08/2020 | -53.42% | HC Wainwright & Co. | $6 → $3 | Maintains | Buy |
| 09/09/2020 | -6.83% | HC Wainwright & Co. | $24 → $6 | Maintains | Buy |
| 09/08/2020 | — | Roth Capital | Downgrades | Buy → Neutral | |
| 09/08/2020 | — | BTIG | Downgrades | Buy → Neutral | |
| 09/08/2020 | — | RBC Capital | Downgrades | Outperform → Sector Perform | |
| 06/17/2020 | 241.61% | BTIG | → $22 | Initiates Coverage On | → Buy |
| 06/04/2020 | 396.89% | Nomura | $12 → $32 | Maintains | Buy |
| 03/26/2020 | 1639.13% | Nomura | → $112 | Initiates Coverage On | → Buy |
| 04/05/2019 | 179.5% | Jefferies | → $18 | Initiates Coverage On | → Buy |
| 03/19/2019 | 334.78% | Oppenheimer | → $28 | Initiates Coverage On | → Outperform |
| 12/26/2018 | 272.67% | HC Wainwright & Co. | → $24 | Initiates Coverage On | → Buy |
| 12/07/2018 | 257.14% | RBC Capital | → $23 | Initiates Coverage On | → Outperform |
| 10/24/2018 | 241.61% | B. Riley Securities | → $22 | Initiates Coverage On | → Buy |
| 09/14/2018 | 459.01% | Cantor Fitzgerald | $32 → $36 | Maintains | Overweight |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 08/09/2023 | 241.61% | 奧本海默 | →$22 | 重申 | 跑贏→跑贏大盤 |
| 2023年05月10日 | 241.61% | 奧本海默 | →$22 | 升級 | →表現強於大盤 |
| 03/08/2023 | -53.42% | HC Wainwright公司 | →$3 | 重申 | →購買 |
| 02/14/2023 | -53.42% | HC Wainwright公司 | →$3 | 重申 | →購買 |
| 10/08/2020 | -53.42% | HC Wainwright公司 | $6→$3 | 維護 | 買 |
| 09/09/2020 | -6.83% | HC Wainwright公司 | $24→$6 | 維護 | 買 |
| 09/08/2020 | - | 羅斯資本 | 評級下調 | 購買→中性 | |
| 09/08/2020 | - | BTIG | 評級下調 | 購買→中性 | |
| 09/08/2020 | - | 加拿大皇家銀行資本 | 評級下調 | 跑贏→板塊表現 | |
| 06/17/2020 | 241.61% | BTIG | →$22 | 開始承保 | →購買 |
| 06/04/2020 | 396.89% | 野村 | $12→$32 | 維護 | 買 |
| 03/26/2020 | 1639.13% | 野村 | →$112 | 開始承保 | →購買 |
| 2019年05月04日 | 179.5% | 傑富瑞 | →$18 | 開始承保 | →購買 |
| 2019/03/19 | 334.78% | 奧本海默 | →$28 | 開始承保 | →跑贏大盤 |
| 2018年12月26日 | 272.67% | HC Wainwright公司 | →$24 | 開始承保 | →購買 |
| 2018年12月07日 | 257.14% | 加拿大皇家銀行資本 | →$23 | 開始承保 | →跑贏大盤 |
| 2018年10月24日 | 241.61% | B.萊利證券 | →$22 | 開始承保 | →購買 |
| 2018年09月14日 | 459.01% | 康託·菲茨傑拉德 | $32→$36 | 維護 | 超重 |
What is the target price for Corbus Pharmaceuticals (CRBP)?
Corbus PharmPharmticals(CRBP)的目標價是多少？
The latest price target for Corbus Pharmaceuticals (NASDAQ: CRBP) was reported by Oppenheimer on August 9, 2023. The analyst firm set a price target for $22.00 expecting CRBP to rise to within 12 months (a possible 241.61% upside). 4 analyst firms have reported ratings in the last year.
奧本海默於2023年8月9日報道了Corbus製藥(納斯達克：CRBP)的最新目標價。這家分析公司將目標價定為2200美元，預計CRBP將在12個月內上漲(可能上漲241.61%)。去年有4家分析公司公佈了評級。
What is the most recent analyst rating for Corbus Pharmaceuticals (CRBP)?
Corbus PharmPharmticals(CRBP)最近的分析師評級是多少？
The latest analyst rating for Corbus Pharmaceuticals (NASDAQ: CRBP) was provided by Oppenheimer, and Corbus Pharmaceuticals reiterated their outperform rating.
最新的分析師對Corbus PharmPharmticals(納斯達克代碼：CRBP)的評級是由奧本海默提供的，Corbus製藥重申了其表現優於大盤的評級。
When is the next analyst rating going to be posted or updated for Corbus Pharmaceuticals (CRBP)?
Corbus PharmPharmticals(CRBP)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Corbus Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Corbus Pharmaceuticals was filed on August 9, 2023 so you should expect the next rating to be made available sometime around August 9, 2024.
分析師在進行了廣泛的研究後得出股票評級，其中包括查閱公共財務報表，與Corbus製藥公司的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Corbus製藥的上一次評級是在2023年8月9日提交的，所以你應該預計下一次評級將在2024年8月9日左右提供。
Is the Analyst Rating Corbus Pharmaceuticals (CRBP) correct?
分析師對Corbus PharmPharmticals(CRBP)的評級正確嗎？
While ratings are subjective and will change, the latest Corbus Pharmaceuticals (CRBP) rating was a reiterated with a price target of $0.00 to $22.00. The current price Corbus Pharmaceuticals (CRBP) is trading at is $6.44, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但Corbus PharmPharmticals(CRBP)的最新評級被重申，目標價在0.00美元至22.00美元之間。Corbus PharmPharmticals(CRBP)目前的交易價格為6.44美元，在分析師的預測範圍內。